Shahhiran, Muhammad Aiman Akmal and Kadir, Mohamad Fairus Abdul and Rashid, Nurshamimi Nor and Abdul-Rahman, Puteri Shafinaz and Othman, Shatrah (2025) Mechanisms of S-phase arrest and mitochondrial dysfunction in complex III by DHODH inhibitors in tumorigenic TNBC cells. Histochemistry and Cell Biology, 163 (1). p. 3. ISSN 0948-6143, DOI https://doi.org/10.1007/s00418-024-02339-0.
Full text not available from this repository.Abstract
Dihydroorotate dehydrogenase (DHODH) inhibitors have recently gained increasing research interest owing to their potential for treating breast cancers. We explored their effects in different breast cancer subtypes, focusing on mitochondrial dysfunction. The sensitivity of different subtypes to the inhibitors was investigated with respect to DHODH expression, tumorigenic, and receptor status. Analysis of respiratory complexes, cell cycle, reactive oxygen species (ROS), and cell differentiation were performed. Four cell lines with different receptor status were included, namely MCF-7, MDAMB-231, SKBR-3, and MCF-10A. We showed that MCF-7 and MDAMB-231 cells of the subtypes (ER+/PR+/HER2-) and (ER-/PR-/HER2-), respectively, were responsive to brequinar. Brequinar (BQR) caused cell cycle arrest in the S-phase in sensitive subtypes of breast cells but induced cell differentiation only in poorly differentiated breast cells. All cell subtypes showed increased generation of ROS, both intracellular and mitochondrial ROS with a greater increase seen in mitochondrial ROS in response to DHODH inhibitor, subsequently contributing to mitochondrial dysfunction. BQR also disrupts the function of complex III in ER+/PR+ and triple negative breast cancer (TNBC) subtypes. Collectively, we have found that MDAMB-231 TNBC cell was the most affected by DHODH inhibition in terms of sensitivity, cell cycle arrest, induction of cell differentiation, production of ROS, and mitochondrial complexes disruption. In conclusion, these findings suggest that DHODH inhibitors can potentially become a valuable targeted therapy for TNBC subtype and further consolidates its therapeutic potential as part of the combinatorial therapy against this resilient breast cancer subtype.
| Item Type: | Article |
|---|---|
| Funders: | Ministry of Education, Malaysia (FRGS/1/2020/SKK0/UM/02/16), Ministry of Higher Education, Malaysia under the Fundamental Research Grant Scheme |
| Uncontrolled Keywords: | Breast cancer; Dihydroorotate dehydrogenase; Differentiation; Tumorigenic; TNBC |
| Subjects: | R Medicine > R Medicine (General) |
| Divisions: | Faculty of Medicine > Department of Molecular Medicine |
| Depositing User: | Ms. Juhaida Abd Rahim |
| Date Deposited: | 20 Mar 2025 04:08 |
| Last Modified: | 20 Mar 2025 04:08 |
| URI: | http://eprints.um.edu.my/id/eprint/47198 |
Actions (login required)
 |
View Item |
